Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Asthma
GSK Data Suggests Efficacy of Advair(R) and Serevent(R) is Not Impacted by Genetic Profile
April 4th, 2008
Data presented today by GlaxoSmithKline showed that genetic differences at the site of the beta-2 adrenergic receptor gene in asthma patients did not lead to different responses to Advair Diskus(R) (fluticasone propionate and salmeterol inhalation powder) or Serevent Diskus(R) (salmeterol xinofoate inhalation powder). Past prospective clinical trials have found that the use of short-acting beta-agonists, such as albuterol, were linked to worse outcomes in patients with asthma with the Arg/Arg genotype of the beta-2 adrenergic receptor gene. In the research presented today, those patients with the Arg/Arg profile responded to Advair (the combination of an inhaled...
Source: Health Business Week (2008-04-04)
|
